CRISM Therapeutics Corporation (LSE:CRTX) is a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs to solid tumours. It is one of the smaller life sciences members of the FTSE AIM All Share Index.

What the company does

CRISM's lead product, ChemoSeed, is designed to be implanted directly into a tumour or into the resection margin after a tumour has been surgically removed, releasing chemotherapy locally rather than throughout the body. The company's initial focus has been on brain tumours, which are a leading cause of cancer death in children and in adults under 40, and it has also received an Innovate UK grant to develop the technology for prostate cancer.

The company joined AIM on 31 May 2024 through the reverse takeover of Amur Minerals Corporation by Extruded Pharmaceuticals, after which the listed company was renamed CRISM Therapeutics Corporation. Amur's former Russian mining assets had already been disposed of in March 2023.

Latest developments

In June 2025, CRISM submitted a Clinical Trial Authorisation application to the UK medicines regulator and completed a fundraising of about £874,000. It has also begun production of a clinical batch of ChemoSeed in preparation for trials.

Financial and dividend picture

As a development-stage company, CRISM does not yet generate product revenue and spends on clinical preparation, manufacturing and regulatory work. It relies on share fundraisings and grants to finance its activities, which can lead to dilution for existing shareholders, and it does not pay a dividend.

Sector and index context

Within the FTSE AIM All Share Index, CRISM Therapeutics sits among a group of healthcare and biotechnology companies that range widely in size and maturity. Biotech valuations are highly sensitive to clinical news, funding conditions and interest rates, and smaller UK-listed companies have often found it difficult to raise capital on attractive terms. Partnerships with larger pharmaceutical groups can provide validation and funding, while regulatory approvals remain the key milestones that can transform a company's prospects.

Key risks

Drug development carries a high risk of failure, and ChemoSeed has yet to complete clinical trials. Regulatory hurdles, manufacturing challenges and competition from other therapies may affect commercial prospects. Dependence on external funding means future fundraisings could dilute holders. As a small AIM stock, the shares may be illiquid and highly volatile around company news.

What to watch next

Investors are likely to focus on the outcome of the clinical trial application, the start of patient dosing, progress on the prostate cancer programme and any partnership discussions. The cash position at CRISM Therapeutics (LSE:CRTX) and any fundraising plans will be particularly important.